ENVALITH

FRONTEO, Inc. 2Q Earnings Call Flash

FRONTEO, Inc. targets 25+ AI drug discovery orders, at least one out-licensing deal and its first US project this fiscal year, with a 2H-weighted plan aimed at a full-year return to profitability

PublishedNovember 16, 2026 at 23:00 GMT+9

Summary

1H consolidated results showed a revenue decline and an operating loss, driven by large contract cancellations in the Risk Management business. The Life Science AI and DX businesses both grew revenue, however, and the portfolio shift toward focus areas is progressing. Management kept the full-year plan unchanged, saying its 2H-weighted profile still holds. It verbally set three concrete targets for the year: AI drug discovery order count, out-licensing, and project wins in the US. Management positioned KIBIT as a core technology in the AI for Science domain, alongside generative AI and physical AI, and stressed its urgency to establish the brand.

Key Points (Earnings Takeaways and Growth Initiatives)

  • Management Strategy and Market View
    • Management views AI for Science as a field that generative AI cannot address and only KIBIT can. Establishing the brand in this domain is the top priority
    • Management notes that 80% of new drugs globally originate from biotech ventures. The company aims to anchor the value chain, from supporting ventures through to out-licensing to pharmaceutical companies
    • Because KIBIT is equation-driven, it delivers high performance on a single PC. Management stressed it has no exposure to debates over massive data centers or power supply
    • In the national initiative to build an AI drug discovery platform, management expects KIBIT AI Biology Lab to serve as the core system
  • Current Business Progress and Drivers
    • In Life Science AI, most costs are fixed (mainly personnel), so revenue growth flows straight through to profit. The segment loss narrowed from JPY -135M in 1Q to JPY -14M in 2Q
    • In BI & Compliance Support, the financial institution segment is performing well. Manufacturers, however, lack a regulatory supervisor, which weakens their incentive to keep using the solution and lies behind the cancellations
    • Economic Security revenue declined due to share loss from aggressive pricing by foreign competitors and reduced usage after staff changes at private-sector clients. Management views this as temporary
    • In BI & Professional Support, new client acquisition is slow mainly because customers do not yet understand how the offering is differentiated from generative AI
  • Key Strategic Initiatives and Inflection Points
    • Novel target discovery, the most technically demanding work, accounts for the largest share of contracted projects. A growing number of clients are moving on to novel target discovery after success in indication discovery
    • A new co-creation project in the renal field has started with Otsuka Pharmaceutical, while projects with Maruho and Santen Pharmaceutical have moved to a second phase. Penetration is advancing among both new and repeat clients
    • Beyond pharma, KIBIT Amanogawa has been adopted by JT and Suntory Global Innovation Center, among others. The company expects to roll it out to any company engaged in R&D
    • In BI & Professional Support, the company is exploring strategic partnerships with generative AI providers. One example is a collaboration in which generative AI turns KIBIT's findings into reports

Outlook and Strategy

  • Full-year plan maintained. Achieving consolidated operating income of JPY 300M requires 2H operating income of JPY 544M (this report's estimate)
  • The FY KPI for AI drug discovery is 25+ orders for co-creation projects and similar engagements. Management described progress as on track based on 1H results
  • The company plans to out-license at least one of its four pipeline assets this fiscal year and to add at least one new out-licensing candidate during the year. The NB Health Laboratory project could be out-licensed as early as FY2026
  • In the US, the company aims to win at least one project this fiscal year and plans to replicate its domestic growth model there
  • DDAIF Innovation Bridge partners are expected to increase to 12–13 companies by fiscal year-end
  • Talk Lab KIBIT is expected to begin monetizing between the end of this fiscal year and next fiscal year. SDS-881 targets regulatory approval in FY2026; management said it would become the world's first conversational AI medical device if approved

Positive Factors

  • According to management, more than 200 people attended CSO Toyoshiba's presentation at AI DDD. Conference attendance has grown tenfold in three years, with major IT and AI players such as Google, NVIDIA and OpenAI now participating
  • Management believes its ability to present concrete cases of elucidating biology and translating it into drug discovery was recognized as rare globally
  • Only KIBIT is used in contracted projects. It is complementary to structure-based AI such as AlphaFold, which operates downstream in the drug discovery process while KIBIT works upstream
  • The company holds 93 active patents worldwide and has secured the capability to analyze Springer Nature literature, creating technical barriers to entry
  • In Economic Security, the revised Corporate Governance Code now explicitly references economic security. Management expects this to drive private-sector adoption, given directors' duty of care
  • The company developed and filed patents for technology that shortens initial supply chain screening from three months to one day, as well as technology that visualizes materials supply networks

Concerns and Risks

  • Life Science AI revenue is recognized based on project progress, causing large quarterly swings and a heavy reliance on 2H build-up
  • The Risk Management segment loss widened from JPY -44M in 1Q to JPY -70M in 2Q, with no visibility on when it will bottom out
  • Cash and deposits fell -27.0% over the half to JPY 1,266M, and the company entered into a JPY 1.22B borrowing agreement in July 2026. Balancing growth investment with financial discipline is a challenge
  • Success-fee revenue has yet to materialize. The timing of the shift to an out-licensing/milestone model depends on development progress at external partners
  • The competitive environment is uncertain, including aggressive pricing by foreign players in Economic Security and slow customer recognition of differentiation from generative AI

Performance Highlights

1H consolidated revenue was JPY 3,292M (-2.5% YoY), with an operating loss of JPY 244M and EBITDA of JPY 16M. Revenue growth in Life Science AI and DX was not enough to offset the decline in Risk Management. The quarterly operating loss narrowed from JPY 180M in 1Q to JPY 70M in 2Q.

Segment Performance

SegmentRevenueYoYOperating IncomeYoY
Life Science AIJPY 384M+40.3%JPY -149M—
Risk ManagementJPY 1,539M-24.2%JPY -114M—
DXJPY 1,429M+32.7%JPY 68M+48.8%
ConsolidatedJPY 3,292M-2.5%JPY -244M—
  • AI Drug Discovery Revenue: JPY 256M (1.3x YoY)
  • Co-Creation Project Orders: 13 as of the earnings call (22 for full prior fiscal year)
  • DDAIF Innovation Bridge Partners: 9 companies (2 of which have moved to the 2nd phase)
  • Revenue Progress vs. Full-Year Plan: Consolidated 43.3%, Life Science AI 25.6%, DX 55.0%
  • Risk Management Revenue by Area: BI & Compliance Support -33.7%, Legal Tech AI -17.2%, Economic Security -40.6% (all YoY)
  • Equity Ratio: 39.5%

Q&A List

  • Q

    Please break down the 40.3% revenue increase in the Life Science AI business.

    A

    1H revenue was JPY 384M, up 40.3% YoY. AI drug discovery in particular grew sharply to JPY 256M, 1.3x the prior-year level. This reflects the accumulation of co-creation projects and DDAIF Innovation Bridge engagements.

  • Q

    Progress against the full-year forecast is 25.6%. Can you achieve the plan?

    A

    As in the previous fiscal year, this business tends to be weighted toward 2H. We expect to achieve our KPI of 25 orders, so we currently assume revenue will come in line with plan. Most of the segment's costs are fixed, mainly personnel, so revenue growth translates directly into profit improvement. We therefore expect operating income to progress in line with plan as well.

  • Q

    You have 13 co-creation project orders so far this year. How does that compare with the target?

    A

    The full-year KPI is currently 25. As of the earnings call, we have received 13 orders across co-creation projects and DDAIF Innovation Bridge. Last year's full-year total was 22, so we believe we are on a solid pace. With Santen Pharmaceutical and Maruho, we have moved to second-phase projects on the back of first-phase results. We have also won projects from new major pharmaceutical companies. We believe our technology is being recognized and that we are tracking well against the target.

  • Q

    KIBIT Amanogawa has been adopted outside pharma, including by JT and Suntory Global Innovation Center. What is the significance of this?

    A

    Our solutions and services are often used in highly established fields such as drug discovery. KIBIT Amanogawa, however, can make a major contribution at the stage of finding the seeds of new research. It analyzes medical and life science papers to capture unreported associations not described in the literature. These discontinuous discoveries support researchers in forming hypotheses. It has been adopted by JT, Suntory Global Innovation Center, GeneNet, Advanced Medical Care and others. We expect usage to expand into food, health, cosmetics and materials. This demonstrates that technology developed in drug discovery can support R&D across a wide range of industries, which will broaden our customer base. New discoveries have historically been difficult and often depended on chance. With KIBIT Amanogawa, researchers can create the triggers for Nobel Prize-level discoveries, not just through inspiration but with an understanding of the underlying causality. In this sense, we believe we can also contribute to the advancement of Japanese science.

  • Q

    You announced your participation in AI DDD in the US. What was the significance?

    A

    We have attended the AI Drug Discovery & Development Summit on an ongoing basis. This year, the event drew not only major global pharmaceutical companies but also leading IT and AI players such as Google, NVIDIA, Amazon, OpenAI and Anthropic, generating significant buzz. Presenting the results we have actually delivered in Japan at such a venue was highly effective. Understanding difficult biology, elucidating disease mechanisms and translating them into drug discovery is something very few have achieved, and it is possible precisely because of KIBIT. These results also come from collaboration between KIBIT and our highly skilled biologists. No comparable combination exists anywhere in the world today, and since KIBIT itself is unique, we are working in fields that only KIBIT can address. Elucidating biology in drug discovery is exactly such a field. We believe there is great value in helping the world understand our AI technology. Japan is not alone in struggling with drug discovery; the entire world faces its difficulties. Showing the world what AI in science looks like and how it can solve these challenges was very meaningful. We believe this will contribute both to expanding our business and to substantially improving drug development globally.

  • Q

    You have strengthened research security support and supply chain investigation services in Economic Security. How have they changed?

    A

    KIBIT Seizu Analysis, used in Economic Security, is based on proprietary AI analytics technology backed by 12 patents, and it has recently been adopted by the Ministry of Finance. Going forward, we believe our solutions can contribute significantly across many areas, particularly inward foreign investment screening, Japan's equivalent of CFIUS in the US. For researcher network analysis, we expanded the scope of papers covered, improved search functionality and enabled monitoring at the organizational level. We have successfully developed applications for practical deployment. Supply chain investigations are highly complex; previously, analysis alone took three months, making the work virtually unmanageable. Advances in our technology have significantly improved this process, and materials analysis is now also possible. We aim to provide new solutions globally and deploy them in practice to help realize effective economic security measures.

  • Q

    How are pricing and revenue recognition timing determined for service revenue in the Life Science AI business? Page 39 of the presentation shows significant quarterly fluctuations rather than steady growth. Is it not structured like usage-fee revenue?

    A

    Life Science AI revenue currently comes from the accumulation of co-creation projects and DDAIF Innovation Bridge engagements, and is recognized based on project progress. As mentioned, we have 13 projects. Revenue grows as more projects overlap, so revenue builds up in 2H.

  • Q

    Do you have a success-fee mechanism? If so, what is it linked to?

    A

    Our current policy is to shift toward services in which we receive success fees tied to out-licensing deals and similar events.

  • Q

    Do Life Science AI clients use multiple tools, including FRONTEO's, on each project? How do they differentiate between tools, or does FRONTEO have exclusivity?

    A

    Projects we are contracted for use our AI, not in combination with other tools. Some clients may use other tools alongside ours, but at least for the work we take on, results are delivered solely with our AI. Our solution is specialized in biology: building hypotheses, exploring targets and identifying indications. At the stage of designing drugs against the disease mechanisms or target molecules we identify, clients may use other AI, such as Google's AlphaFold, to analyze protein structures and design drugs that fit the target. In our area of responsibility, however, clients currently use only our AI.

Disclaimer

ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.

  • Purpose and Disclaimer Regarding Investment Decisions

    This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.

  • Information Sources, Accuracy, and Disclaimer of Warranty

    This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.

  • Limitation of Liability

    ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.

  • Potential Conflicts of Interest

    ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.

  • No Obligation to Change or Update Content

    The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.

  • Governing Language

    This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.

  • Copyright

    All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.

  • Use for Other Investment Products

    Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.